



## GNAO1 Neurodevelopmental Disorder – Bow Foundation 2023 Grant Program

The Bow Foundation, will provide a 1-year grant to support research related to GNAO1 Neurodevelopmental Disorder. Up to 2 awards will be granted at \$100,000 each.

### Background

GNAO1 (G Protein Subunit Alpha O1) is a protein coding gene. Most patients with a GNAO1 neurodevelopmental disorder are diagnosed as infants or young children. Many of the patients begin experiencing seizures, abnormal movements and developmental delays in their infancy. The seizures are often refractory, and the patients seem to cycle through numerous medications as they try to find relief. The abnormal movements seem to worsen as the patients age. Several patients have benefited from deep brain stimulation surgery, including the youngest patient in the world to receive the procedure (a 2-year-old in the UK).

The Orphan Disease Center, in collaboration with the Bow Foundation, is seeking grant applications that aim to further progress our understanding of the disease, the available therapeutic options, and investigating strategies to establish outcome measurements. The RFA could focus on one, or several, of the following aims to further advance GNAO1 research and therapeutic approaches:

- Novel therapeutic approaches, including, but not limited to, techniques in genome editing, RNA-based mechanisms, biologics, novel cell-based therapeutics, and development of novel therapeutic compounds, including through small molecule repurposing or screening against validated phenotypes in human cellular systems.
- Identification of short-term biomarkers that can monitor disease activity and treatment response.
- Establishment of outcome measures for future clinical trials.
- Development of therapeutic approaches in early symptomatic patients.
- Supporting pilot clinical trials, preclinical trials, or animal model trials that promote drug repurposing strategies.
- Development of a standardized evaluation criteria for clinical projects allowing uniformity of patients as well as the severity and progression of the disease.
- Development of cellular models (i.e. oligodendrocytes) for evaluation of therapeutic options to translate for clinical use.



### Eligibility

All individuals holding a faculty-level appointment at an academic institution or a senior position at a non-profit institution or foundation are eligible to respond to this RFA.

### Letter of Interest Instructions

All applicants must first submit a one-page Letter of Interest (LOI) to be reviewed for consideration of a full application submission. Please submit your LOI by March 3, 2023.

Full Proposal: By invitation only, please submit your full application documents by April 14, 2023.

### FORMAT for documents

Font and Page Margins: Use Arial typeface, a black font color, and a font size of 11 points. A symbol font may be used to insert Greek letters or special characters. Use 0.5-inch margins (top, bottom, left, and right) for all pages, including continuation pages. Print must be clear and legible; all text should be single-spaced.

Header: There should be a header at the top right on all pages of the PDF indicating the full name of the PI (e.g., PI: Smith, John D.).

For your convenience, a continuation page template is included at the end of the application document.

File names: ALL files to be uploaded should start with the LAST NAME of the PI followed by the brief name of the document. Examples: SMITH CV, SMITH Cover Page, SMITH Budget. If files are not labeled properly, you will be asked to resubmit the PDFs before your application can be considered.

### CONTENT to be uploaded

Cover Page/Checklist/Institutional Signature Page [PDF]. An application template will be provided.

Biosketch/CV, with key personnel supporting the project (5 pages max). [PDF]

The PI must include accurate and complete information regarding all other sources of grant support (current and pending), including title, abstract, annual and total amount of grant, inclusive funding period, and percent effort. PI should add a section listing key personnel working on the project. Any Co-Is/Co-PIs, if present, should also provide a biosketch/CV.

Detailed Budget and Justification. [combined into one PDF]

Complete Excel budget sheet (to be provided). Describe justifications in a Word document including all subcontracts to co-investigators.



Research Plan (5 pages max) and Bibliography (1 page max) [combined into one PDF]  
Include the following sections: Specific Aims, Background and Significance, Preliminary Studies/Data, Research Design and Methods. Research plan should address the following questions: 1) Do you require access to reagents, animal models, patient blood samples, IRB/ethical board approvals, and/or equipment necessary to complete work? If so, please describe your plan to gain access within the time-frame of this grant period. 2) Have you identified qualified personnel to complete this project within the grant period? If not, please provide your plan to do so. Text citations should use a numbered format. Include all author names in the reference list.

Appendix [combined into one PDF]  
Limited to 5 pages of supplemental information pertaining to proposal or preliminary data only; maximum of 3 relevant reprints are also acceptable. Include IRB and/or IACUC approval letters if relevant. Include letters of support or letters of collaboration, if available.

#### Project Disclosures and No Cost Extensions (NCE)

- NCEs will be granted at the discretion of the Bow Foundation.
- Awardees will be limited to 1 NCE request for their award.
- Maximum NCE time awarded will be 6 months.
- NCEs will be granted after a formal request prior to the NCE deadline with adequate justification.
- If granted an NCE, you are still required to submit an interim scientific report 6 months into the duration of the original award period, regardless of your new project end date.
- In your letter of interest, you will be required to certify that you have identified qualified personnel to complete this project within the grant period PRIOR to the start date of the award. If you have not, you will be required to provide your plan to engage said personnel. Only under extenuating circumstances will personnel issues be considered for NCE requests.
- In your letter of interest, you will also be required to state whether or not you require access to reagents, cell lines, animal models, IRB/ethical board approvals, and/or equipment necessary to complete your work. If so, you will be required to describe your plan to gain access within the time-frame of this grant period.

#### Grant Review Procedure

- Grants will be reviewed for scientific content and relevance to the goals of the RFA.
- Full applications proceed through a two-step review process. The first step includes external review and rating with an assessment of the strengths and weaknesses of each application based on the defined review criteria described below. During the second step, funding recommendations are determined based on an assessment of the reviewer scores and written comments. Final decision of funding will be made by Center Leadership.

Proposal Content and Review Criteria: The following criteria will be utilized in proposal



review.

- Project Proposal – Is the proposed project of high scientific quality? Is the budget fully justified and reasonable in relation to the proposed project?
- Background – Is the fundamental objective of the study and hypothesis to be addressed clearly defined?
- Scientific Approach - Will the proposed specific aims answer the study hypothesis? Will the scientific approach effectively test and answer each specific aim? Are the study goals supported by existing data? Is the research plan feasible within the time frame proposed?
- Clinical Impact - Is the answer to the study hypothesis important to our ability to understand the mechanisms behind GNAO1? Will the proposed research lead to substantial advances and/or contribute to large leaps of understanding or knowledge that will aid efforts towards GNAO1 treatment?
- Research Significance - Does the study address an important question that is not likely to be addressed without this funding? Does the proposed study offer a unique opportunity to explore an important issue and/or employ a novel approach to this disease research? Will the study outcomes advance our knowledge of this disease and/or contribute to changes in the focus of future research questions or the way we conduct research on this issue?
- Investigator Qualifications - Do investigators hold a track record of outstanding accomplishment as evidenced by peer-review publications and funding awards in the area of proposed research? Do the investigators have access to the resources and environment necessary to complete the study as outlined? Is the research proposal appropriately designed to individual investigator area of expertise? Do investigators also have a track record of collaborative multi-institutional peer-reviewed publications?
- Future Funding - Will the study generate preliminary data that will allow the PI to obtain further funding in the future? Will the outcome of this study put the PI in a position to continue their work in the GNAO1 space?

Proposed funding period is one year, beginning about one month after full applications are received.

Allowable direct costs

- Salary for PI
- Salary/stipend and related benefits for graduate



student/postdoctoral

fellow/technical support

- Travel (up to \$1500)
- Laboratory supplies and other research expenses
- IDCs of 10% are included in the total award amount

Unallowable costs

- Consultant costs
- Tuition
- Professional membership dues
- Equipment >\$5,000
- General office supplies, institutional administrative charges (e.g., telephone, other electronic communication, IT network, etc.)
- Pre-award charges
- Any other expenses not directly related to the project